image: Targeting Phage Therapy 2023 will gather 20+ Industrials. view more
Credit: Credits to Targeting Phage Therapy.
More than 125 international participants from 27 different countries will be joining Targeting Phage Therapy 2023 on June 1-2 in Paris. During Targeting Phage Therapy 2023, 50+ communications will be presented in the form of major talks, short orals, and posters. Targeting Phage Therapy 2023 gives you the chance to network with industrials who will be presenting their latest data and innovations.
Targeting Phage Therapy 2023 Overview: Speakers & Chairs
Targeting Phages 2023 will address how phages play a strategic role to combat infection and antibiotic resistance, but also to modulate gut microbiota. Phage enthusiasts and experts will be presenting their latest data and innovations.
Session 1 – Phage Therapy: A Glance Throughout the Years – Chaired by Domenico Frezza
Martha Clokie, University of Leicester, United Kingdom
Challenges and Opportunities for Bacteriophage Therapy
Domenico Frezza, University of Roma Tor Vergata, Italy
Phage Therapy: Vision, Gaps and Evolution
Mzia Kutateladze, Eliava Institute of Bacteriophage, Georgia
Bacteriophage Therapy: From Soviet Clinical Experience to Current Activities at the Eliava Institute
Session 2 - Phage Therapy in Action: A Glimpse Within the Nations – Chaired by Martha Clokie, by Cara Fiore and William Summers
William Summers, Yale University, USA
Historical Reflections of the Trials and Tribulations of Phage Therapy: 1930-1950
Lilian Musila, U.S. Army Medical Research Directorate, Kenya
Potential of Therapeutic Phages to Combat MDR ESKAPE Pathogens in Developing Nations
Jean-Paul Pirnay, Queen Astrid Military Hospital, Belgium
Bacteriophages: It’s a medicine, Jim, but not as we know it
Jessica Sacher, Cofounder of Phage Directory, Australia
Scaling Phage Therapy, Starting with Phage Australia
Ryszard Międzybrodzki, Hirszfeld Institute of Immunology and Experimental Therapy PAS, Poland
Phages in the Medical Research Activity in Poland
Pranav Johri, Founder of Vitalis Phage Therapy, India
From Patient to Advocate – Introducing Phage Therapy to India
Tristan Ferry, Hospices Civils de Lyon, France
The Use of Bacteriophage Therapy for Complex Bacterial Infections: the PHAGEinLYON Experience
Jolien Onsea, KU Leuven, Belgium
The Use of Bacteriophage Therapy for Difficult-to-Treat Musculoskeletal Infections: the PHAGEFORCE Experience
Cara Fiore, Food and Drug Administration (FDA), USA
The Regulation of phage therapy applications in humans in the USA
Session 3 – Bacteriophages & Microbiota: On the Way to a Medical Revolution? – Chaired by Mzia Kutateladze and Marvin Edeas
Marvin Edeas, Université de Paris, INSERM 1016, Institut Cochin, France
Introduction to Bacteriophages & Microbiota: On the Way to a Medical Revolution
Martial Marbouty, Institut Pasteur, France
Phage-Bacteria Interaction Network in Human Intestinal Tract
Session 4 - Bacteriophages Today: Prophylactic & Therapeutic Potential – Chaired by Anna Pistocchi
Noemi Poerio, University of Rome Tor Vergata, Italy
A Novel Combined Host- and Pathogen-Directed Therapeutic Approach to Fight Infections by MDR- Klebsiella pneumoniae
Farzaneh Moghtader,
Combined Therapies of Wound Infections with Phages/MSCs Aggregates
Mariagrazia Di Luca, University of Pisa, Italy
Phage-based drugs for the treatment of biofilm-associated infections
Anna Pistocchi, Università degli Studi di Milano, Italy
Investigating the Therapeutic Potential of Phages as Antibacterials and Immunomodulators in a Zebrafish Model of Cystic Fibrosis
Session 5 - Phage Therapy: Towards Amplification and Innovation – Chaired by Anders S. Nilsson and Jean-Paul Pirnay
Mina Pastagia, Armata Therapeutics, USA
Safety, Pharmacokinetics, and Antibacterial Activity of AP-PA02 Multi-phage Cocktail in Patients with Cystic Fibrosis and Chronic Pulmonary Pseudomonas aeruginosa Infection (SWARM-P.a. Clinical Trial)
Alexander Sulakvelidze, President and CEO of Intralytix, Inc., USA
Modern Approaches for Optimizing Therapeutic Phage Preparations
Aleksandra Petrovic Fabijan, Westmead Institute for Medical Research, Australia
Therapeutic Monitoring of Phage Therapy
Anthony Maresso, TailΦr Labs, Baylor College of Medicine, USA
Phage 3.0: Spotlighting the Viral Genosphere for Drug Discovery, Biotechnology, and Novel Biological Functions
Anders S. Nilsson, Stockholm University, Sweden
Novel Computer Program for Modelling Bacteriophage Infection Kinetics
Austen Terwiliger, TailΦr Labs, Baylor College of Medicine, USA
Retrospective outcomes of personalized phage therapy for ESKAPE pathogen
Rodrigo Ibarra Chavez, University of Copenhagen, Denmark
Phage-inducible Chromosomal Islands Promote Genetic Variability by Blocking Phage Reproduction
Short Oral Presentations & Innovations: 10 minutes to convince - Chaired by Mariagrazia Di Luca and Martial Marbouty
Who is Attending Targeting Phage Therapy 2023?
Industrial participants: Armata Pharmaceuticals (USA), Cellexus (UK), Aparon (UK), AusHealth (Australia), Biochimpharm JSC (Georgia), BIOCODEX (Paris), BIOMERIEUX SA (France), COBIK (Slovenia), ERYTECH Pharma (France), Intralytix, Inc. (USA), MB Pharma s.r.o. (Czech Republic), Optipharm Inc. (Republic of Korea), Phage Directory (Australia), Phagos (France), Pherecydes Pharma (France), Proteon Pharmaceuticals S.A. (Poland), Resistell (Switzerland), Rime Bioinformatics (France), SET Medikal (Turkey), Vitalis Phage Therapy (India)…
Academic participants: Agricultural University of Athens, Chungnam Natl. Univ., Comenius University, Consejo Superior de Investigaciones Científicas, Corpo De Bombeiros Militar Do Amazonas, CY Paris Cergy Université, Deutsches Zentrum für Infektionsforschung, Eliava Institute of Bacteriophages, microbiology and virology, Eötvös Loránd University, Food and Drug Administration (FDA), Fundação Universidade Aberta Da Terceira, Fundación AZTI, Geneva University Hospitals, German Center for Infection Research, Hirszfeld Institute of Immunology and Experimental Therapy, Hôpitaux Unversitaires de Genève, Hospices Civils de Lyon, IDADE, IIBR, Ilia state university, Instituto de Biología Integrativa de Sistemas (I2SysBio) Universitat de València-CSIC, Israel Institute for Biological Research, Istanbul University, KU Leuven, Laboratoire M2iSH, Masaryk University, Max Planck Institute for Medical Research, Medical center Francesc Macia, MPI, National Taiwan University, North-West Unversity, Pharmabiotic Research Institute, Prof. Waclaw Dabrowski Institute of Agricultural and Food Biotechnology - State Research Institute, Queen Astrid Military Hospital, Stockholm University, The Chinese University of Hong Kong, Umeå University, Universidade de Aveiro, Universidade Federal de São Paulo, Università degli Studi di Milano, Università del Piemonte Orientale "A. Avogadro", Universitat de València, Université Clermont Auvergne, University College London, University Hospital Regensburg, University of Copenhagen, University of Edinburgh, University of Exeter, University of Leicester, University of Milano, University of Pisa, University of Rome Tor Vergata, University of Verona, US Army Medical Research Directorate – Georgia, Victor Babeş University of Medicine and Pharmacy, Westmead Institute for Medical Research, Yale University, TiHo Hannover…
PHAGE Therapy, Applications, and Research Journal is the Official Partner of Targeting Phage Therapy 2023
Attendees will have the chance to network with the Editor in Chief during Targeting Phage Therapy 2023 and discuss about future collaboration.
Targeting Phage Therapy 2023: 10 Minutes to Convince
The abstract submission process is still open. Targeting Phage Therapy 2023 will dedicate a session for the latest research and innovations in the field of phages and phage therapy. You will have 10 minutes to convince and present your work.
Armata Pharmaceuticals and Cellexus will showcase their latest innovations during Targeting Phage Therapy 2023.
Targeting Phage Therapy 2023 Media Partners: Phage Directory and Bacteriophage.news.